Asian Pacific Journal of Cancer Prevention

  • 제16권7호
  • /
  • Pages.2659-2664
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Cyr61/CCN1 Overexpression Induces Epithelial-Mesenchymal Transition Leading to Laryngeal Tumor Invasion and Metastasis and Poor Prognosis

  • Liu, Ying (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Zhou, Yan-Dong (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Xiao, Yu-Li (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Li, Ming-Hua (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Wang, Yu (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Kan, Xuan (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Li, Qiu-Ying (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Lu, Jian-Guang (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University) ;
  • Jin, De-Jun (Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University)
  • 발행 : 2015.04.14
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: To examine the expression of cysteine-rich 61 (Cyr61/CCN1) protein in laryngeal squamouscell carcinoma (LSCC) tissues, and its relationship with the tumor epithelial-mesenchymal transition (EMT), invasion, metastasis, and prognosis. Materials and Methods: Immunohistochemistry was used to detect the expressions of Cyr61, Vimentin (Vim), and E-cadherin (E-cad) in 88 cases of LSCC tissues and 30 cases of tumor-adjacent normal tissues. Vim and E-cad were used as mesenchymal and epithelial markers, respectively, to determine the relationship between Cyr61 expression and the EMT of LSCC cells. In addition, clinical and histopathological data were combined to analyze the relationship between the positive-expression rates of Cyr61, Vim and E-cad and LSCC invasion, metastasis and prognosis. Results: In LSCC tissues, Vim expression rate was significantly higher than that of the tumor-adjacent tissues, whereas E-cad expression rate was significantly lower than that of the tumor-adjacent tissues. The Vim expression rate was significantly higher in stages T3 and T4 than in stages T1 and T2 LSCC tissues, whereas E-cad expression rate was significantly lower in stages T3 and T4 than in stages T1 and T2 LSCC tissues. Compared to the group without lymph node metastasis, the Vim expression rate was significantly higher and the E-cad expression rate was significantly lower in the group with lymph node metastasis. The expression rate of Cyr61 was significantly higher in LSCC tissues than in the tumor-adjacent normal tissues. In addition, the Cyr61 expression rate was higher in stages T3 and T4 than in stages T1 and T2 LSCC, and higher in the group with lymph node metastasis than in the group without lymph node metastasis. The Vim expression rate was significantly higher in the Cyr61 positive group than in the Cyr61 negative group, whereas the E-cad expression rate was significantly higher in the Cyr61 negative group than in the Cyr61 positive group. Survival analysis indicated that survival rates of Cyr61 positive, Vim positive and E-cad negative groups were significantly lower than that of Cyr61 negative, Vim negative and E-cad positive groups, respectively. Conclusions: Cyr61 expression is closely associated with LSCC invasion and lymph node metastasis. Overexpression of Cyr61 may induce EMT and therefore leads to LSCC invasion and metastasis and poor prognosis. Cyr61 may become a new maker for clinical prediction of LSCC invasion and metastasis and a new target for LSCC treatment.

키워드

참고문헌

  1. Bartholin L, Wessner LL, Chirgwin JM, Guise TA (2007). The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett, 246, 230-6. https://doi.org/10.1016/j.canlet.2006.02.019
  2. Baum B, Settleman J, Quinlan MP (2008). Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol, 19, 294-308. https://doi.org/10.1016/j.semcdb.2008.02.001
  3. Bleau AM, Planque N, Perbal B (2005). CCN proteins and cancer: two to tango. Front Biosci, 10, 998-1009. https://doi.org/10.2741/1594
  4. Chen C, Zimmermann M, Tinhofer I, Kaufmann AM, Albers AE (2013). Epithelial-to-mesenchymal transition and cancer stem (-like) cells in head and neck squamous cell carcinoma. Cancer Lett, 338, 47-56. https://doi.org/10.1016/j.canlet.2012.06.013
  5. Chen CC, Lau LF (2009). Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol, 41, 771-83. https://doi.org/10.1016/j.biocel.2008.07.025
  6. Chien W, Kumagai T, Miller CW, et al (2004). Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem, 279, 53087-96. https://doi.org/10.1074/jbc.M410254200
  7. Cichon MA, Radisky DC (2014). Extracellular matrix as a contextual determinant of transforming growth factor-b signaling in epithelial-mesenchymal transition and in cancer. Cell Adh Migr, 8, 588-94. https://doi.org/10.4161/19336918.2014.972788
  8. Crockett JC, Schutze N, Tosh D, et al (2007). The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology, 148, 5761-8. https://doi.org/10.1210/en.2007-0473
  9. Dhar A, Ray A (2010). The CCN family proteins in carcinogenesis. Exp Oncol, 32, 2-9.
  10. Genini M, Schwalbe P, Scholl FA, Schafer BW (1996). Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer, 66, 571-7. https://doi.org/10.1002/(SICI)1097-0215(19960516)66:4<571::AID-IJC24>3.0.CO;2-9
  11. Grant CM, Kyprianou N (2013). Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Transl Androl Urol, 2, 202-11.
  12. Hou CH, Lin FL, Hou SM, Liu JF (2014). Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer, 13, 236. https://doi.org/10.1186/1476-4598-13-236
  13. Jandova J, Beyer TE, Meuillet EJ, Watts GS (2012). The matrix protein CCN1/CYR61 is required for ${\alpha}\;(V){\beta}5$-mediated cancer cell migration. Cell Biochem Funct, 30, 687-95. https://doi.org/10.1002/cbf.2853
  14. Juric V, Chen CC, Lau LF (2012). $TNF{\alpha}$-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release. PLoS One, 7, 31303 https://doi.org/10.1371/journal.pone.0031303
  15. Lau LF, Nathans D (1985). Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J, 4, 3145-51.
  16. Lau LF (2011). CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci, 68, 3149-63. https://doi.org/10.1007/s00018-011-0778-3
  17. Leu SJ, Chen N, Chen CC, et al (2004). Targeted mutagenesis of the angiogenic protein CCN1 (CYR61). Selective inactivation of integrin alpha6beta1-heparan sulfate proteoglycan coreceptor-mediated cellular functions. J Biol Chem, 279, 44177-87. https://doi.org/10.1074/jbc.M407850200
  18. Lin CM, Liang CZ (2014). Cyr61: a potential therapeutic target for prostate cancer. Asian J Androl, 16, 788-9. https://doi.org/10.4103/1008-682X.128517
  19. Lu JG, Li Y, Li L, Kan X (2011). Overexpression of osteopontin and integrin ${\alpha}v$ in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol, 137, 1613-8. https://doi.org/10.1007/s00432-011-1024-y
  20. Maity G, Mehta S, Haque I, et al (2014). Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization. Sci Rep, 4, 4995.
  21. Menendez JA, Vellon L, Mehmi I, et al (2005). A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene, 24, 761-79. https://doi.org/10.1038/sj.onc.1208238
  22. Monnier Y, Farmer P, Bieler G, et al (2008). CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res, 68, 7323-31. https://doi.org/10.1158/0008-5472.CAN-08-0841
  23. Mori A, Desmond JC, Komatsu N, et al (2007). CYR61: a new measure of lung cancer outcome. Cancer Invest, 25, 738-41. https://doi.org/10.1080/02770900701512597
  24. Roth P, Silginer M, Goodman SL, et al (2013). Integrin control of the transforming growth factor-${\beta}$ pathway in glioblastoma. Brain, 136, 564-76. https://doi.org/10.1093/brain/aws351
  25. Sampath D, Zhu Y, Winneker RC, Zhang Z (2001). Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab, 86, 1707-15.
  26. Schmitz P, Gerber U, Schutze N, et al (2013). Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4. Thromb Haemost, 110, 1046-54. https://doi.org/10.1160/TH13-02-0158
  27. Sin WC, Bechberger JF, Rushlow WJ, Naus CC (2008). Dose-dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J Cell Biochem, 103, 1772-82. https://doi.org/10.1002/jcb.21571
  28. Su JL, Chiou J, Tang CH, et al (2010). CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway. J Biol Chem, 285, 31325-36. https://doi.org/10.1074/jbc.M109.087122
  29. Sung YK, Kwack MH, Kim SR, Kim MK, Kim JC (2008). Transcriptional activation of CCN1 and CCN2, targets of canonical Wnt signal, by ascorbic acid 2-phosphate in human dermal papilla cells. J Dermatol Sci, 49, 256-9. https://doi.org/10.1016/j.jdermsci.2007.09.005
  30. Tabatabai G, Moch H, Tritschler I, et al (2013). Integrin control of the transforming growth factor-${\beta}$ pathway in glioblastoma. Brain, 136, 564-76. https://doi.org/10.1093/brain/aws351
  31. Todorovic V, Chen CC, Hay N, Lau LF (2005). The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol, 171, 559-68. https://doi.org/10.1083/jcb.200504015
  32. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R (2002). Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene, 21, 178-85.
  33. Wang Y, Zhou BP (2013). Epithelial-mesenchymal Transition-a hallmark of breast cancer metastasis. Cancer Hallm, 1, 38-49. https://doi.org/10.1166/ch.2013.1004
  34. Xie D, Miller CW, O'Kelly J, et al (2001). Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem, 276, 14187-194.
  35. Xie JJ, Xu LY, Xie YM, et al (2011). Involvement of Cyr61 in the growth, invasiveness and adhesion of esophageal squamous cell carcinoma cells. Int J Mol Med, 27, 429-34.
  36. Yang J, Weinberg RA (2008). Epithelial-mesench;ymal transition: at the crossroads of development and tumor metastasis. Dev Cell, 14, 818-29. https://doi.org/10.1016/j.devcel.2008.05.009
  37. Zuo GW, Kohls CD, He BC, et al (2010). The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol, 25, 795-806.

피인용 문헌

  1. Suppression of the Epidermal Growth Factor-like Domain 7 and Inhibition of Migration and Epithelial-Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Cells vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4065
  2. Early Growth Response Protein-1 Involves in Transforming Growth factor-β1 Induced Epithelial-Mesenchymal Transition and Inhibits Migration of Non-Small-Cell Lung Cancer Cells vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4137
  3. Knockdown of Snail inhibits epithelial–mesenchymal transition of human laryngeal squamous cell carcinoma Hep-2 cells through the vitamin D receptor signaling pathway vol.95, pp.6, 2017, https://doi.org/10.1139/bcb-2017-0039
  4. KLF7 overexpression in human oral squamous cell carcinoma promotes migration and epithelial-mesenchymal transition vol.13, pp.4, 2017, https://doi.org/10.3892/ol.2017.5734
  5. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process vol.19, pp.1, 2019, https://doi.org/10.1186/s12885-019-5282-4